Proceedings of The First Current Topic in Infectious Diseases
Overview of Conjugate Pneumococcal Vaccine: Serotype Coverage, Efficacy and Status of Usage in other Countries
Streptococcus pneumoniae remains a major cause of morbidity and mortality even in the developed countries. It is one of the commonest causes of community-acquired pneumonia, bacteraemia, meningitis, acute otitis media, sinusitis, and postsplenectomy sepsis.6 Currently available vaccines target the polysaccharide capsule, whose antiphagocytic property is a major virulence factor. Of the 90 described capsular types, the 23 commonest types are included in the polysaccharide vaccine, which provides coverage against 80% to 90% of bacteraemic isolates.7,8 The polysaccharides, however, are poorly immunogenic in children less than two years of age that are most susceptible to invasive pneumococcal infections. Pneumococcal polysaccharides are therefore conjugated to proteins to improve their immunogenicity in young children and infants. A heptavalent conjugate pneumococcal vaccine was licensed in 2000 in the United States, which contains serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. CRM197, a non-toxic variant of diphtheria toxin, is used as the protein conjugate. These seven serotypes accounted for 86% of bacteraemia, 83% of meningitis, and 65% of acute otitis media in children less than six years of age in the United States. In a randomized, double-blinded clinical trial in which ~37,000 children were recruited, the heptavalent vaccine is ~100% effective in preventing invasive pneumococcal infections caused by vaccine serotypes and 89% against all serotypes. There is a 7.0%-22.8% reduction in the incidence of otitis media and a 5.3% reduction in antibiotic use in the vaccinees. The vaccine is presently licensed for use in infants older than six weeks and is given at two, four, six months, with a booster dose at 12-15 months. It is recommended for children less than 23 months old; for children aged 24-59 months, it should be considered for those who are predisposed to severe pneumococcal disease. A 40%-50% reduction in nasopharyngeal pneumococcal carriage of vaccine serotypes is found in field trials of a 9-valent conjugate vaccine.
1. Yang Y, Shen X, Jiang Z, et al. Study on Haemophilus influenzae type b diseases in China: the past, present and future. Pediatr Infect Dis J 1998;17:S159-S165.
2. Lau YL, Yung R, Low L, Sung R, Leung CW, Lee WH. Haemophilus influenzae type b infections in Hong Kong. Pediatr Infect Dis J 1998;17:S165-S169.
3. Lau YL. Haemophilus influenzae type b diseases in Asia. Bull.World Health Organ 1999;77:867-8.
4. Levine OS, Schwartz B, Pierce N, Kane M. Development, evaluation and implementation of Haemophilusinfluenzae type b vaccines for young children in developing countries: current status and priority actions. Pediatr Infect Dis J 1998;17:S95-S113.
5. Heath PT. Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Pediatr Infect Dis J 1998;17:S117-S122.
6. American Academy of Pediatrics. American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 2000;106: 362-6.
7. Hausdorff WP, Bryant J, Kloek C, Paradiso PR, Siber GR. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis 2000;30:122-40.
8. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000;30:100-21.
9. Yang Y, Leng Z, Lu D. Pediatric Haemophilus influenzae type b meninngitis in Hefei city: an epidemiologic study. Chung Hua I. Hsueh Tsa Chih 1998;78:251-3.
10. Levine OS, Liu G, Garman RL, Dowell SF, Yu S, Yang YH. Haemophilus influenzae type b and Streptococcus pneumoniae as causes of pneumonia among children in Beijing, China Emerg Infect Dis 2000;6:165-70.
11. Yang Y, Shen X, Vuori-Holopainen E, et al. Sero-etiology of acute lower respiratory infections among hospitalized children in Beijing. Pediatr Infect Dis J 2001;20:52-8.
12. Lau YL, Low LC, Yung R, et al. Invasive Haemophilus influenzae type b infections in children hospitalized in Hong Kong, 1986-1990. Hong Kong Hib Study Group. Acta Paediatr 1995;84:173-6.
13. Sung RY, Cheng AF, Chan RC, Tam JS, Oppenheimer SJ. Epidemiology and etiology of pneumonia in children in Hong Kong. Clin Infect Dis 1993;17:894-6.
14. Ho PL, Que TL, Tsang DN, Ng TK, Chow KH, Seto WH. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob. Agents Chemother 1999;43:1310-3.
15. Ho PL, Yam WC, Cheung TKM, et al. Rapid rise of fluoroquinolone resistance among Streptococcus pneumoniae in Hong Kong linked to acquisition of fluoroquinolone resistance by the locally dominant Spanish 23F clone. Emerg Infect Dis 2001. In press.
16. Luey KY, Kam KM. Vaccine coverage of Streptococcus pneumoniae in Hong Kong with attention to the multiple-antibiotic-resistant strains. Vaccine 1996;14:1573-80.